Breast cancer therapy in China: Introducing the Special Collection-Reference-Cited by-同舟云学术

Breast cancer therapy in China: Introducing the Special Collection

Published:2024-03-25 Issue:S8 Volume:130 Page:1368-1370
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Wang Xiaojia¹²,O’Regan Ruth M.³^ORCID

Affiliation:

1. Department of Medical Oncology (Breast Cancer) Cancer Hospital of University of Chinese Academy of Sciences Hangzhou China

2. Department of Medical Oncology Yiwu Hospital, Affiliated to Hangzhou Medical College Yiwu Zhejiang China

3. Department of Medicine University of Rochester Medical Center Rochester New York USA

Abstract

This special issue indirectly reflects the medical level and research hotspots of breast cancer experts in China in recent years as well as the treatment level and disease outcome of patients with breast cancer in China, allowing readers to appreciate the achievements made in the field of breast cancer in China in recent years and to identify the gaps in the international field.

Publisher

Wiley

Reference10 articles.

1. Development and evaluation of a risk assessment tool for the personalized screening of breast cancer in Chinese populations: A prospective cohort study

2. Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects

3. Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer

4. Real‐world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis

5. Cyclin‐dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple‐negative breast cancer by affecting the immune microenvironment